GuidelineEuropean radiology2024
Soft tissue tumor imaging in adults: European Society of Musculoskeletal Radiology-Guidelines 2023-overview, and primary local imaging: how and where?
Guideline in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- MRI of soft tissue tumours: a structured "8S framework" aligned with WHO 2020 classification.Skeletal radiology · 2026Review
- Structural and Functional Principles in Quadriceps Reconstruction.Muscles (Basel, Switzerland) · 2026Review
- [Soft tissue sarcoma of the extremities-imaging, biopsy planning, and pitfalls in radiology].Radiologie (Heidelberg, Germany) · 2026Review
- Multiparametric US and MRI Features of Femoral Myxoid Liposarcoma-Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Evaluation of magnetic resonance imaging parameters and compliance with guidelines in soft tissue sarcomas.BMC cancer · 2026Article
- Whole-tumor histogram analysis of synthetic MRI for the differentiation of benign and malignant soft-tissue tumors: a preliminary study.European radiology · 2025Article
- Soft Tissue Masses of the Hand.Seminars in musculoskeletal radiology · 2025Review
- Diagnostic work-up of lipomatous tumors: a decision-making analysis among European sarcoma centers.Insights into imaging · 2025Article
- Diagnostic Delay in Soft Tissue Sarcomas: A Review.Cancers · 2025Review
- Preoperative differentiation of retroperitoneal ganglioneuroma and schwannoma using an ultrasonography-based multivariable model and simplified score: development and single-center internal validation.Frontiers in surgery · 2025Article
- Review
- Magnetic Resonance Imaging Texture Analysis Based on Intraosseous and Extraosseous Lesions to Predict Prognosis in Patients with Osteosarcoma.Diagnostics (Basel, Switzerland) · 2024Article
- Current state of spinal nerve sheath tumor management and future advances.Neuro-oncology advances · 2024Review
- Beyond Clinical Examination: Utilizing MRI Surveillance to Detect Recurrence of Soft Tissue Sarcomas and Differentiate from Posttherapeutic Changes.Biomedicines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEarly, accurate diagnosis is crucial for the prognosis of patients with soft tissue sarcomas. To this end, standardization of imaging algorithms, technical requirements, and reporting is therefore a prerequisite. Since the first European Society of Musculoskeletal Radiology (ESSR) consensus in 2015, technical achievements, further insights into specific entities, and the revised WHO-classification (2020) and AJCC staging system (2017) made an update necessary. The guidelines are intended to support radiologists in their decision-making and contribute to interdisciplinary tumor board discussions. MATERIALS AND
methodsA validated Delphi method based on peer-reviewed literature was used to derive consensus among a panel of 46 specialized musculoskeletal radiologists from 12 European countries. Statements were scored online by level of agreement (0 to 10) during two iterative rounds. Either "group consensus," "group agreement," or "lack of agreement" was achieved.
resultsEight sections were defined that finally contained 145 statements with comments. Overall, group consensus was reached in 95.9%, and group agreement in 4.1%. This communication contains the first part consisting of the imaging algorithm for suspected soft tissue tumors, methods for local imaging, and the role of tumor centers.
conclusionUltrasound represents the initial triage imaging modality for accessible and small tumors. MRI is the modality of choice for the characterization and local staging of most soft tissue tumors. CT is indicated in special situations. In suspicious or likely malignant tumors, a specialist tumor center should be contacted for referral or teleradiologic second opinion. This should be done before performing a biopsy, without exception. CLINICAL RELEVANCE: The updated ESSR soft tissue tumor imaging guidelines aim to provide best practice expert consensus for standardized imaging, to support radiologists in their decision-making, and to improve examination comparability both in individual patients and in future studies on individualized strategies. KEY POINTS: • Ultrasound remains the best initial triage imaging modality for accessible and small suspected soft tissue tumors. • MRI is the modality of choice for the characterization and local staging of soft tissue tumors in most cases; CT is indicated in special situations. Suspicious or likely malignant tumors should undergo biopsy. • In patients with large, indeterminate or suspicious tumors, a tumor reference center should be contacted for referral or teleradiologic second opinion; this must be done before a biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.